Skip to main content

Perspective Therapeutics to Participate in Upcoming Investor Conferences in December

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

SEATTLE, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

36th Annual Piper Healthcare Conference
Date: December 3, 2024
Location: New York, NY
Format: Fireside Chat
Time: 10:00-10:25 AM ET

7th Annual Evercore HealthCONx
Date: December 5, 2024
Location: Coral Gables, FL
Format: Fireside Chat
Time: 10:50-11:10 AM ET

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website at https://perspectivetherapeutics.com/investor-center

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.



Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

Russo Partners, LLC
Nic Johnson

PerspectiveIR@russopr.com

Primary Logo

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  248.28
+0.00 (0.00%)
AAPL  273.05
+0.00 (0.00%)
AMD  274.95
+0.00 (0.00%)
BAC  53.95
+0.00 (0.00%)
GOOG  335.40
+0.00 (0.00%)
META  670.91
+0.00 (0.00%)
MSFT  418.07
+0.00 (0.00%)
NVDA  202.06
+0.00 (0.00%)
ORCL  177.58
+0.00 (0.00%)
TSLA  392.50
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.